Ireland· IE-PA-PA22992/026/003
Lacosamide Grindeks 150 mg film-coated tablets
A lacosamide product containing lacosamide, registered in Ireland by AS Grindeks. The same ATC class is registered in 18 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Lacosamide is registered in 18 of 19 countries.
Countries holding a registration under ATC N03AX18 (lacosamide), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 10 of them publish a price we can compare per daily dose
Lacosamide · ATC N03AX18
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lacosamide costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), the median price runs from $0.48 in United States to $3.11 in Switzerland — a ×6.4 gap.
- 4 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Lacosamide · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$3.11
- IT Italy$3.06
- FR France$1.49
- US United States$0.48 (acquisition cost)
The record
At a glance
HPRA (Ireland)- Active substance
- Lacosamide
- Manufacturer
- AS Grindeks
- Country
- Ireland (IE)
- ATC code
- N03AX18
- ATC class
- Lacosamide
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberPA22992/026/003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
62 interactions on record for lacosamide.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lacosamide · interactions on record
62 records
- 5 severe
- 32 moderate
Most severe, free to view
- DolasetronA04AA04severe
- CeritinibL01ED02severe
- CeritinibL01XE28severe
- SiponimodL04AA42severe
25 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lacosamide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaARKVIMMANeuraxpharm Bohemia s.r.o., Praha
- SpainBALMID 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULA EFGIntas Third Party Sales 2005 S.L.
- United StateslacosamideMSN LABORATORIES PRIVATE LIMITED
- NetherlandsCosim 150 mg filmomhulde tablettenGedeon Richter Plc.
- SwitzerlandLacosamid Desitin
- ItalyLACOSAMIDE ACCORDACCORD HEALTHCARE SLU
- SwedenLacosamide 1A Farma 150 mg Filmdragerad tablett1A Farma A/S
- FranceLACOSAMIDE ACCORD 150 mg, comprimé pelliculéACCORD HEALTHCARE (ESPAGNE)
Authorised across Europe · EMA
The same active substance is authorised in 30 EEA countries. Names it is sold under:
- Austria · Lacopat, Lacopat Packung Zur Behandlungseinleitung
- Belgium · Lacosamid Hikma, Lacosamide Eg
- Bulgaria · Канилад, Лакозамид Гриндекс
- Cyprus · Kanilad, Lacosadel
- Czechia · Arkvimma, Kanilad
- Germany · Kanilad, Lackepila
- Denmark · 200 mg, Lacosamid Opko Health Spain
- Estonia · Kanilad, Lacosamide Alembic
- Spain · Balmid, Kanilad
- Finland · Lacosamide Fresenius Kabi, Lacosamide Grindeks
- France · Lacosamide Arrow, Lacosamide Biogaran
- United Kingdom (Northern Ireland) · Lacosamide, Lacosamide Amarox
- Greece · Anlamyl, Josamec
- Croatia · Kanilad, Lacosamide Grindeks
- Hungary · Anlamyl, Arkvimma
- Iceland · Josamec, Lacosamide Accord
- Italy · Lacosamide Aurobindo, Lacosamide Doc
- Liechtenstein · Lacosamid Fresenius Kabi, Lacosamide Accord
- Lithuania · Lacosamide Fresenius Kabi, Lacosamide Grindeks
- Luxembourg · Lacosamide Eg
- Latvia · Kanilad, Lacosamide Fresenius Kabi
- Malta · Anlamyl, Kanilad
- Netherlands · Cosim, Lacosamide Amarox
- Norway · Lacosamide Accord, Lacosamide Fresenius Kabi
- Poland · Arkvimma, Epilantin
- Portugal · Lacosamida Alter, Lacosamida Aristo
- Romania · Lacosamidă Teva
- Sweden · Lacomed, Lacosamide 1a Farma
- Slovenia · Lacosabil, Lacosamide Grindeks
- Slovakia · Arkvimma, Kanilad
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c686c3d0-fd3b-46fe-8477-859d61387f6a GET /v1/drugs/c686c3d0-fd3b-46fe-8477-859d61387f6a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"N03AX18"
],
"strength": null,
"pa_number": "PA22992/026/003",
"substances": [
"Lacosamide"
],
"legal_basis": "Generic application (Article 10(1) of Directive No 2001/83/EC)",
"market_info": "Not marketed",
"authorised_at": "12/12/2025",
"dispensing_status": "Product subject to prescription which may be renewed (B)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about lacosamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.